With the recent accelerated approval from the FDA for Genentech’s Polivy for patients with relapsed or refractory diffuse large B-cell lymphoma this is a fantastic step forward in the ADC space. The excitement and the potential that lies in the space is more apparent than ever.
Celebrating its tenth year, World ADC San Diego will take place from October 8-11 at the Manchester Grand Hyatt San Diego. As the world’s largest gathering of ADC stakeholders, World ADC San Diego is where investment, development and partnership decisions are made and where the potential within the field comes to life.
According to Elayda Program Director, World ADC: “As the industry’s longest standing and most comprehensive antibody-drug conjugate conference, World ADC San Diego is the definitive opportunity for researchers and developers to gain and utilize key learnings in an open environment of knowledge sharing and exchange. The tenth year of this leading event will as ever bring the best content including a focus on what the industry needs right now”.
Over 600 drug developers from 230 active ADC organizations will join together to define their 2020 ADC development strategy. Designed with thought-leaders at Seattle Genetics, AstraZeneca and ImmunoGen this industry defining event will share the pioneering advances with next generation ADC technologies, in depth development case studies with supporting data and learnings from clinical failures. It will feature over 100 presentations from 88+ expert speakers and 60 scientific posters on the top innovations in ADC science within the past year.
Research presented this year shows how the scientific community continues to harness new technologies and insights to improve upon and develop more effective cancer treatments. These include an update on Regeneron’s non-cytotoxic ADC that has the potential to treat
Atherosclerosis and Endocyte’s radioconjugate that utilizes a high affinity targeting ligand to direct potent radiotherapy to prostate cancer cells.
It will also include an update from Pfizer on lessons learned from “Back-to-Back” Regulatory Submissions for Two ADC Products and from AbbVie on Lessons Learned from Combination Therapy with Telisotuzumab Vedotin, an MMAE ADC Target c-Met, in NSCLC.
Key highlights will include:
- 4 in-depth streams from discovery to manufacturing and commercialization
- 10 interactive and open workshops addressing key challenges across all levels of development
- 3 Focused Seminar Days delving deeper into the most exciting opportunities including ADCs in combination
- A dedicated 2 hour Poster session as part of the agenda – to highlight the most recent projects and breaking findings in ADC development
- The inaugural CMC Day – hear from Novartis, Immunogen and Focussed from Phase II through to commercial scale manufacturing
- ‘Celebrating 10 years of World ADC’ – an informal evening to hear from patients, clinicians and celebrate 10 years of this exciting field
- Talks from companies who haven’t spoken at World ADC before including GSK, Menarini and Zymeworks
- Updates from some of the most exciting ADCs in the clinic such as those from Daiichi Sanko, AbbVie and Immunomedics
- New Clinical Operations Stream. As the clinical progress of ADCs evolves rapidly, so do the clinical challenges. To reflect this the clinical stream will have more focus on the operational and practical challenges of running a clinical trial
- Expanded Focus ADC & Combinations Day. One of the hottest topics currently in the ADC field; the use of ADCs in combination. This year the scope has been broadened to all combination approaches to enable attendees to review the landscape of ADCs in combination and its true potential.
About Antibody-drug Conjugate Therapies:
Antibody-drug conjugates (ADCs) are effective biological drugs designed to treat cancer in a more targeted manner and are at the forefront of oncology therapeutics. ADCs are complex molecules which harness an antibody (to search out the disease) with an anti-cancer agent such as a payload or drug (to kill the cancer). This enables the cancer cells to be targeted effectively without damage to other, healthy cells.
There is continued enthusiasm for antibody-drug conjugates (ADCs) as a cornerstone in cancer treatment. Currently there are 5 approved ADCs (Mylotarg (Pfizer), Besponsa (Pfizer), Kadcyla (Genentech/Roche), Adcetris (Seattle Genetics/Takeda)) and Polivy (Genentech) and 86+ in clinical development. In the last few months there have been more promising clinical results for ADCs such as Enfortumab vedotin (Seattle Genetics) and DS-8201 (Daiichi Sankyo).
New areas such as novel ADC technologies (payloads, linkers, antibody engineering), ADCs and immuno-oncology and ADCs outside of oncology are all bringing renewed momentum to the space.
About World ADC:
World ADC is the industry’s definitive forum for learning and networking. www.worldadc-usa.com. World ADC San Diego will feature its Scientific Poster session (Thursday October 10) with 60+ scientific posters. As part of the conference, the 6th Annual World ADC Awards (Thursday October 10) will recognize the extraordinary endeavors, teamwork and commercial acumen that has propelled the field to the forefront of cancer research today.
Senior Partners
Ajinomoto Bio-Pharma Services
Mersana
ImmunoGen
Seattle Genetics
Femtogenix
Lonza
NJ Bio
Contacts:
Jenny Barlow
Divisional Head of Marketing, Hanson Wade
E-mail: Jenny.Barlow@hansonwade.com
